PTEN antagonist peptide (PAP4)

PTEN antagonist peptide (PAP4)

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

TVEEPSNPEASSSTSVTPGRKKRRQRRRPQ

Thr-Val-Glu-Glu-Pro-Ser-Asn-Pro-Glu-Ala-Ser-Ser-Ser-Thr-Ser-Val-Thr-Pro-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln

30

95.4%

C₁₃₉H₂₄₁N₅₃O₄₈

3422.78

Synthetic

Powder

PTEN antagonist peptide (PAP4) is a 30-amino acid peptide designed to inhibit phosphatase and tensin homolog (PTEN), a central neuron-intrinsic inhibitor of axon growth potential that operates via the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. PAP4 binds to the C-terminal portion of PTEN, resulting in PTEN inhibition and can cross the blood-brain barrier. In a chronic model of cervical contusion spinal cord injury, systemic administration of PAP4 promoted robust growth of descending bulbospinal rVRG axons within the denervated portion of the phrenic motor neuron (PhMN) pool located caudal to the injury site.

PAP4 treatment led to a significant increase in both the number and total length of rVRG axon profiles in the phrenic nucleus region, with a 5-8 fold increase in axon numbers compared to control conditions. This axonal growth was associated with partial recovery of diaphragm motor activity, as measured by electromyography (EMG) amplitude, though this functional effect depended on the anesthetic regimen used during recording. The observed axon growth occurred in a region critical for controlling diaphragmatic respiratory function, suggesting PAP4 can stimulate significant re-growth of damaged respiratory neural circuitry in a chronic injury setting.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Ohtake Y, Park D, Muneer PMA, Li H, Xu B, Sharma K, Smith GM, Selzer ME, Li S. The effect of systemic PTEN antagonist peptides on axon growth and functional recovery after spinal cord injury. Biomaterials. 2014 May;35(16):4610-26. doi: 10.1016/j.biomaterials.2014.02.037. Epub 2014 Mar 12. PMID: 24630093; PMCID: PMC4195449.
• Michel-Flutot P, Cheng L, Thomas SJ, Lisi B, Schwartz H, Lam S, Lyttle M, Jaffe DA, Smith G, Li S, Wright MC, Lepore AC. PTEN inhibition promotes robust growth of bulbospinal respiratory axons and partial recovery of diaphragm function in a chronic model of cervical contusion spinal cord injury. bioRxiv [Preprint]. 2024 Jan 11:2024.01.10.575021. doi: 10.1101/2024.01.10.575021. Update in: Exp Neurol. 2024 Aug;378:114816. doi: 10.1016/j.expneurol.2024.114816. PMID: 38260313; PMCID: PMC10802567.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.